Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

85 trials

NCT06568601
Recruiting
Pharmacogenomic Informed Statin Prescribing
Not applicable · United States · 2 sites
Registry update: 2 Nov 2026
NCT06894251
Recruiting
Effect of LIMICOL®-NG on Plasma LDL-cholesterol Concentration in Subjects with Moderate Hypercholesterolemia
Not applicable · France · 1 site
Registry update: 25 Mar 2025
NCT06597006
Recruiting
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Phase 3 · Austria, China, Germany, United Kingdom, Greece, Malaysia, Netherlands, Taiwan, United States, South Africa · 19 sites
Registry update: 24 Jul 2026
NCT06894004
Recruiting
Mechanism of Ketogenic Diet-Induced Hypercholesterolemia
Not applicable · United States · 1 site
Registry update: 23 Mar 2026
NCT06833944
Recruiting
High Intensity Interval Training in the Treatment of Familial Hypercholesterolemia (UPPA-FH)
Not applicable · Spain · 1 site
Registry update: 22 Sept 2026
NCT06501443
Recruiting
LATAM LOWERS LDL-C
Phase 4 · Argentina, Brazil · 8 sites
Registry update: 30 Dec 2025
NCT06555120
Recruiting
Screening for Familial Hypercholesterolemia in Children
Not applicable · France · 1 site
Registry update: 12 Feb 2026
NCT06810466
Recruiting
Evaluation of the Effects of Two Dietary Supplement Formulations on the Lipid Profile in Mild Hypercholesterolemia
Not applicable · Italy · 1 site
Registry update: 5 Feb 2025
2023-507489-20-00
Recruiting
Optimizing therapy with n=1-studies: negating the 'nocebo' effect in statin-intolerance
Phase 4 · Netherlands · 11 sites
Registry update: 27 Aug 2026
NCT06597019
Recruiting
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Phase 3 · Argentina, Austria, Belgium, Brazil, China, Czechia, Germany, Spain, France, United Kingdom, Greece, Hong Kong, Hungary, Israel, Italy, Malaysia, Netherlands, Poland, Portugal, Taiwan, United States, South Africa · 60 sites
Registry update: 15 May 2026
NCT06568471
Recruiting
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Phase 3 · China · 18 sites
Registry update: 6 Feb 2025
NCT06451770
Recruiting
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
Phase 1 · Australia, Canada, United Kingdom, Netherlands, United States, South Africa · 18 sites
Registry update: 23 Oct 2026
NCT06422741
Recruiting
Effect of a Grape Seed Proanthocyanidin Extract (GSPE) on LDL Cholesterol Levels in Rotating Night Shift Workers
Not applicable · Spain · 2 sites
Registry update: 27 Aug 2025
NCT06471036
Recruiting
Test 2 Treat: Can we Improve the Testing and Treatment of High Cholesterol in Patients Who Have Been Hospitalized for a Cardiac Event by Providing Education to Doctors and Patients?
Not applicable · United States · 1 site
Registry update: 16 Oct 2026
NCT06488105
Recruiting
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Phase 2 · United States · 1 site
Registry update: 27 Feb 2026
NCT06535542
Recruiting
Integrating Whole Genome Sequencing and Digital Twins Into the Management of Hypercholesterolemia in Emiratis
Not applicable · United Arab Emirates · 1 site
Registry update: 25 Mar 2025
NCT06747000
Recruiting
Lipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid Disorders
Not applicable · United States · 2 sites
Registry update: 1 Oct 2025
NCT06439654
Recruiting
Atlantic Lipid Lowering Treatment Optimization Program
Not applicable · United States · 2 sites
Registry update: 3 Aug 2025
NCT07491172
Recruiting
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
Phase 1 · Australia, United Kingdom, New Zealand, United States · 17 sites
Registry update: 18 Sept 2026
NCT06858982
Recruiting
PMMHRI-Pitavastatin Registry
Not applicable · Poland · 1 site
Registry update: 5 Mar 2025

Ordered by registry start date. Freshness and sponsorship never change the order.